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Non-invasive prenatal testing (NIPT) for aneuploidy using cell-free DNA in maternal plasma
has been widely adopted. Recently, NIPT coverage has expanded to detect subchromoso-
mal abnormalities including the 22q11.2 deletion. Validation of a SNP-based NIPT for detec-
tion of 22q11.2 deletions demonstrating a high sensitivity (97.8%) and specificity (99.75%)
has been reported. We sought to further demonstrate the performance of a revised version
of the test in a larger set of pregnancy plasma samples.
Methods
Blood samples from pregnant women (10 with 22q11.2-deletion–affected fetuses and 390
negative controls) were successfully analyzed using a revised SNP-based NIPT for the
22q11.2 deletion. The sensitivity and specificity of the assay were measured.
Results
Sensitivity of the assay was 90% (9/10), and specificity of the assay was 99.74% (389/390),
with a corresponding false positive-rate of 0.26%.
Discussion
The data presented in this study add to the growing body of evidence demonstrating the abil-
ity of the SNP-based NIPT to detect 22q11.2 deletions with high sensitivity and specificity.
Introduction
Non-invasive prenatal testing (NIPT) using cell-free DNA from maternal plasma has altered the
landscape of prenatal screening, owing to its improved performance over traditional screening
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techniques [1, 2]. Clinical adoption of prenatal screening for commonly observed aneuploidies
has been rapid since its introduction in 2011 [2]. Recently, NIPT coverage has expanded to inc-
lude a range of sub-chromosomal abnormalities with high penetrance and severe phenotypes,
including the 22q11.2 deletion syndrome (22q11.2 DS also known as DiGeorge or velocardiofa-
cial syndrome) [3–5].
With a reported population-wide frequency of 1 in 3,000–6,000 live births, 22q11.2 DS
is the most common microdeletion syndrome [6, 7]. Several reports suggest a higher pre-
natal prevalence, with an estimated frequency of approximately 1 in 1000 [4, 8, 9]. 22q11.2
DS is characterized by a spectrum of clinical manifestations with varying degrees of sever-
ity, including congenital heart defects, immune dysfunction, hypocalcemia, mild-to-severe
learning disabilities, and an increased risk of mental health disorders in adulthood [10].
Due to the variability in presentation, diagnosis based on clinical findings is challenging,
and 22q11.2 DS remains undiagnosed in approximately one third of affected infants. For
those cases diagnosed prenatally, appropriate prenatal counselling addressing the variable
phenotype of the condition offers expectant couples the opportunity to make informed
reproductive decisions and plan for prenatal and neonatal patient management. Patients
who do not receive a perinatal diagnosis often undergo a lengthy process of evaluation by
multiple specialist providers before a definitive diagnosis by molecular cytogenetics is
reached [10].
For individuals with 22q11.2 DS pregnancy, changes in management such as delivery at spe-
cialized neonatal care centers may be advised and early therapeutic intervention can positively
affect clinical outcomes [11]. For example, the majority (~87%) of deaths associated with the
syndrome are attributed to congenital heart defects, [10] but appropriate care at birth can redu-
ce related mortality by ~12% [12]. Likewise, hypocalcemia-induced seizures can be optimally
managed by close monitoring of calcium levels and providing calcium supplementation as
needed [13, 14]. Currently there is a paucity of information about the phenotype for 22q11.2
deletion cases that are ascertained through NIPT and how detection translates into improved
long-term outcomes.
Previously, validation of a targeted single–nucleotide-polymorphism (SNP)-based test tar-
geting the 22q11.2 deletion (~3 Mb A–D region) demonstrated an analytical detection rate of
97.8% and a false positive rate of 0.76% [8]. In that study, only three affected pregnancy plasma
samples were analyzed along with 43 artificially generated mixture samples. The paucity of
pregnancy plasma samples was considered a key limitation of the study [15]. Herein, we pres-
ent results from an analytical validation of a revised version of the 22q11.2 deletion assay in a
cohort consisting entirely of pregnancy plasma samples.
Methods
Ethics statement
Pregnant women were enrolled at six collaborating prenatal centers and all samples were
collected in accordance with the following institutional review board (IRB)-approved pro-
tocols: Columbia University IRB (Columbia University, New York, NY), The Children’s
Hospital of Philadelphia Research Institute IRB Children’s Hospital of Philadelphia, PA),
Western IRB (Saint Peter’s University Hospital, New Brunswick, NJ; GenoMed, Inc. Lees-
burg, FL; Advanced Bioscience Resource, Alameda, CA) and Biomed IRB (StemExpress,
Placerville, CA). A signed informed consent was obtained from all enrolled participants.
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or options to stock, in the company. BL is a paid
consultant to Natera. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
Study samples
Two tubes of blood (approximately 20 ml) were obtained from study participants who under-
went amniocentesis or chorionic villus sampling; the study groups consisted of 10 women with
a confirmed molecular diagnosis of fetal 22q11.2 deletion (nine women initially ascertained
through ultrasound abnormalities often associated with 22q11.2DS; one woman had no prior
risk indications associated with the disorder) and 409 women with a confirmed unaffected preg-
nancy based on molecular analysis (with no ultrasound findings suggestive of the disorder). For
each sample, information regarding maternal age and gestational age of the patient at the time
of the blood draw, and time between invasive procedure and blood draw was requested. Out-of-
specification samples (i.e., gestational age<9 weeks, blood draw for NIPT performed post-fetal
demise, samples with smaller nested proximal or atypical distal deletions (~13% of 22q11.2 dele-
tions [8, 16], or inability to determine truth from an invasive-testing sample were excluded
from the study analysis. A second sample was not requested for cases with no NIPT results. All
cases were de-identified prior to NIPT analysis. The study was internally blinded; blinding with
was overseen by one of our academic collaborators (BL) who served as an auditor.
Single–nucleotide-polymorphism-based analyses
Maternal plasma samples were analyzed at Natera’s Clinical Laboratory Improvement Act-certi-
fied, and College of American Pathologists-accredited laboratory using an updated SNP-based
screening methodology. The protocol uses a single set of pooled targeted primers to perform a
massively multiplexed PCR (mmPCR) amplification targeting SNPs covering chromosomes 13,
18, 21, 22, X, and Y. The target set contains 13,926 distinct genetic loci, including 1,351 SNPs
spanning a 2.91 Mb section of the 22q11.2 region that constitutes ~87% of all deletions detected
in individuals with the 22q11.2 DS. Following amplification, samples were sequenced using the
NextSeq 500 platform (Illumina, Inc., San Diego, CA) at a standard depth of read (~ 4.7x106
reads/sample), and SNP allele ratios were determined (Panorama Precision Genomics SaaS Plat-
form, V 2.0.12.0) to generate a fetal copy number for the 22q11.2 region. Risk status for the
22q11.2 deletion was assigned as “high risk” (0.95 confidence for the presence of the 22q11.2
deletion), “low risk” (0.90 confidence for the absence of the deletion), or “risk unchanged”/”no
calls” (lower confidence values for both the presence and absence of the deletion) [8]. “High-risk”
calls with maternally deleted haplotypes were reflexively sequenced at a higher depth of read
(~14x106 reads/sample) to confirm “high-risk” status. For cases with a fetal fraction of 2.8–6.5%,
the sample was evaluated only for the presence or absence of the paternally-inherited haplotype.
Data analysis
Comparison of patient demographics between the unaffected and affected groups was per-
formed using independent samples t-tests for the difference between the means; p-values
were 2-sided, and the significance level was set at 0.05. Sensitivity and specificity of the test
to detect the 22q11.2 deletion were determined after reflex resequencing. Sensitivity was cal-
culated as the proportion of cases with the 22q11.2 deletion that were identified “high-risk”
for the 22q11.2 deletion by NIPT. Specificity was calculated as the proportion of truly unaf-
fected cases that were assigned a “low-risk” status for the 22q11.2 deletion. Samples reported
as “risk unchanged” or “no-call” were excluded from specificity calculations.
Based on a prevalence of 1/1442 for A–D deletions associated with 22q11.2 DS detected by
the SNP-based test in the clinical population [16], an estimated positive predictive value (PPV)
for the test was calculated by employing the standard formula, (sensitivityprevalence)/ (sensi-
tivityprevalence + (1-specificity)(1-prevalence)) [17], which uses estimated prevalence, sensi-
tivity, and specificity.
Non-invasive prenatal screening for 22q11.2 deletion
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Results
To validate the performance of the updated SNP-based technology in detecting the 22q11.2
deletion, 419 pregnancy plasma samples with known fetal copy number for the 22q11.2 region
were evaluated. The study included 10 samples with a confirmed affected fetus (Table 1) and
409 samples with an unaffected fetus for the 22q11.2 deletion, as determined by chromosomal
microarray (5 affected samples), fluorescence in situ hybridization (FISH) (4 affected samples),
or massively multiplexed PCR (mmPCR)/NGS analysis (1 affected, 409 unaffected samples) [8]
on fetal genetic material obtained from an invasive procedure. For all samples, the mother was
determined to be disomic based on analysis of the maternal circulating free DNA (cfDNA).
Among the 10 affected samples, the deletion was confirmed by array or mmPCR to occur
in the common A–D region in six samples and deletion sizes ranged from 2.55–3.16 Mb. The
remaining four affected samples were confirmed by FISH and were conservatively treated as
having the full ~3 Mb A–D deletion (Table 1). In 8 of the 10 affected samples, the blood draw
for NIPT was performed2 days following the invasive procedure; in the other 2 cases, blood
was drawn prior to the invasive procedure (Table 1). Of the 409 unaffected pregnancy plasma
samples, 19 (4.6%) received a no-call due to low fetal fraction (fetal fraction <2.8%; n = 10), or
inability of the algorithm to make a high confidence call (n = 9).
The mean maternal age for the affected samples was 28.1 weeks compared to 26.0 weeks
for unaffected samples (p-value of 0.351). The gestational age range was higher (mean 21.7
weeks, range 13.4–37.6) for the affected samples compared to the unaffected samples (mean
12.8 weeks, range 9.0–27.0) with a p-value of 0.005. The affected samples also had a higher
fetal fraction distribution (mean 16.6%, 7.9–39.7%) compared to the unaffected samples
(mean 9.4%, 2.8–31.0%) with a p-value of 0.04 (Table 2).




















1 22q11.2 N/A 22.0 13.3 Amnio CMA 2.55 15 High
risk
Paternal
2 22q11.2 19 15.6 11.7 CVS mmPCR 2.91 0 High
risk
Paternal
3 22q11.2 20 30.4 15.4 Amnio FISH N/A 53 High
risk
Maternal
4 22q11.2 21 21.5 39.7 Amnio CMA 2.55 14 High
risk
Maternal
5 22q11.2 35 13.3 19.4 CVS FISH N/A 6 High
risk
Maternal
6 22q11.2 31 20.2 7.9 Amnio CMA 2.55 0 High
risk
Maternal
7 22q11.2 35 25.1 8.0 Amnio CMA 3.15 15 Low
risk
N/A
8 22q11.2 30 16.2 21.4 Amnio FISH N/A 6 High
risk
Maternal
9 22q11.2 31 14.0 9.6 CVS FISH N/A 2 High
risk
Paternal
10 22q11.2 31 37.4 19.3 Amnio CMA 2.55 109 High
risk
Maternal
Amnio, amniocentesis; CMA, chromosomal microarray; CVS, chorionic villus sampling; FF, fetal fraction; FISH, fluorescence in situ hybridization; GA, gestational age;
MA, maternal age; mmPCR, massively-multiplexed polymerase chain reaction; N/A, not available, NIPT, non-invasive prenatal testing.
Blood draws were performed prior to procedures.
https://doi.org/10.1371/journal.pone.0193476.t001
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Of the 10 affected pregnancy samples, 9 were identified as high-risk (test positive) and 1 was
identified as low-risk (test negative), generating a sensitivity of 90% (9/10; 95% confidence inter-
val, 55.5–99.75%) (Table 3). All high-risk calls were further evaluated for both paternal and mat-
ernal haplotypes to identify the parental source of the 22q11.2 deletion. Of the 9 samples that
received a high-risk call, 6 were found to be deleted on the maternally inherited chromosome
and 3 on the paternally inherited chromosome (Table 1). Of the 390 unaffected samples, one
false positive case was reported (gestational age 15 weeks; fetal fraction 8.5%; no evidence of
chromosomal anomalies in the CVS sample), generating an observed specificity of 99.74%
(389/390; 95% confidence interval, 98.58%–99.99%) (Table 3) with a corresponding false posi-
tive rate of 0.26% (95% confidence interval, 0.01–1.42%). Low-risk calls for 99 unaffected cases
with fetal fraction ranging from 2.8–6.5% were based on the analysis of only the paternal allele.
Based on a prevalence of 1/1442 in the clinical pregnancy population for the A–D 22q11.2 dele-
tion [16], the estimated PPV is 19.6% (Table 3).
Discussion
Previously, we reported that the SNP-based NIPT detects the fetal 22q11.2 deletion (~3 Mb
A–D deletion) with a sensitivity of 97.8% and a false positive rate of 0.76% [8]. To reduce
the false positive rate and lower the barrier to clinical adoption, the assay was revised in
three ways. First, the number of targeted SNPs in the 22q11.2 region was increased from
672 to 1,351. Second, the algorithm’s positive-call confidence threshold was raised from
0.90 to 0.95 [16]. Finally, reflex sequencing of “high-risk” calls with maternally-deleted hap-
lotypes at higher depth of read was implemented [4]. Data from this validation of the revised
test on 400 pregnancy plasma samples (which included 10 affected samples) demonstrated a
sensitivity of 90% and a false positive rate of 0.26%, in line with expected assay performance
Table 2. Patient characteristics of study samples.
Patient Characteristics Affected Samples (n = 10) Unaffected Samples (n = 390) p-value
Maternal Age (Years)‡
Mean ± SD 28.1 ± 6.4 26.0 ± 5.3 0.351
Median (Range) 31.0 (19.0–35.0) 25 (18.0–40.0)
Gestational Age (Weeks)
Mean ± SD 21.7 ± 7.7 12.8 ± 3.2 0.005
Median (Range) 21.0 (13.4–37.6) 12.4 (9.0–27.0)
Fetal Fraction (%)
Mean ± SD 16.6 ± 9.5 9.4 ± 4.2 0.04
Median (Range) 14.4 (7.9–39.7) 8.8 (2.8–31.0)
At date of blood draw.
‡Maternal age data were available for 9/10 affected samples.
https://doi.org/10.1371/journal.pone.0193476.t002
Table 3. Sensitivity, specificity, and estimated positive predictive value for 22q11.2 A–D deletions.
Sensitivity, % (n) (95% CI) 90.0 (9/10) (55.50–99.75)
Specificity, % (n) (95% CI) 99.74 (389/390) (98.58–99.99)
Prevalence 1/1442 [16]
Estimated Positive Predictive Value, % 19.6
Calculated by the standard formula for estimating PPV based on prevalence, sensitivity, and specificity
https://doi.org/10.1371/journal.pone.0193476.t003
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given the methodological improvements and previous reports [8, 16]. Of note, this SNP-
based test is designed to detect the large A–D 22q11.2 deletion that is associated with
22q11.2 DS[8, 16]. Performance of the assay has not yet been assessed for smaller deletions
within the A-D region. Thus, a conservative estimate of the detection rate under the
assumption that none of these smaller deletions are identifiable would be approximately
78.3% [the proportion of all 22q11.2 DS that consist of full A–D deletions (87%) x the mea-
sured sensitivity of the assay for the full A–D deletions (90%)]. Based on a prenatal test
referral prevalence of 1/1442 for full A–D deletions (or 1/1225 for all significant deletions in
A–D deletions) the PPV was 19.6%. Alternately, using a population-wide prevalence num-
ber of 1/4,000 [6, 7], the estimated PPV of the assay would be 8.1%. The PPV of this assay
was directly measured in a clinical population previously and was found to be 44.2% [16].
The false positive rate with the revised methodology was 0.26% compared with 0.76% in the
previous validation study [8]. However, precise measurement of a false positive rate close to
zero requires a very large study cohort. A clinical experience study reporting results in more
than 70,000 samples tested for fetal 22q11.2 deletion yielded an estimated false positive rate of
0.07% when using the same revised protocol [16]. Although clinical follow-up was not avail-
able for all women in that study, an estimate of the false positive rate was made using the con-
servative assumption that all “high-risk” cases lost to follow-up were false positives, yielding an
upper-bound false positive rate estimate of 0.09% and a corresponding specificity of 99.91%.
Caution should be exercised, however, when interpreting false positive rates—false positive
cases may harbor smaller deletions in 22q11.2 that could remain undetected by FISH, which is
often used as the confirmatory test for subchromosomal imbalances. Confined placental mosa-
icism might also contribute to the false positive rate [18].
A limitation of this study is the higher gestational age distribution of the affected pregnancy
cases compared with those typically observed in a clinical cohort. The higher gestational age is
attributed to the delay in identifying and procuring samples from affected pregnancies. As ges-
tational age and fetal fraction are positively correlated, higher fetal fractions among the affected
pregnancies would be expected to affect the assay’s performance. Note that in our previous vali-
dation study, which used mixture samples, the fetal fraction distribution of the affected samples
was specifically designed to approximate that of a clinical cohort [8], and in that study, the sensi-
tivity was comparable to the sensitivity observed in this study. Another factor that may affect
fetal fraction is the time between the invasive procedure (CVS or amniocentesis) and the blood
draw for NIPT. Although it has been suggested that fetal fraction may rise immediately follow-
ing an invasive procedure [19], another study reported no evidence of an increase in fetal frac-
tion 24 hours following a CVS procedure [20]. All blood samples in this study were either
drawn prior to, or>24 hours after invasive procedures.
The relative rarity of the 22q11.2 deletion makes it challenging to assemble a patient cohort
closely resembling a clinical population for use in a validation study. Historically, validation
studies for rare conditions required alternative approaches—e.g., testing maternal plasma
diluted with DNA from an affected individual [8, 21]. As NIPT coverage expands to include
rarer conditions, indication-specific analytic validations using affected pregnancy plasma sam-
ples, as obtained for this study, will prove increasingly difficult to do, and alternative validation
approaches will become necessary. It is therefore notable that in this study, consisting entirely
of pregnancy plasma samples, the demonstrated assay performance was comparable to that
reported in a previous study that used a substantial number of simulated pregnancy samples
[8]. Another recent study reported the performance of a microarray-based cfDNA test for the
detection of the 22q11.2 deletion that included approximately 120 affected lab-generated preg-
nancy plasma samples [22], further supporting the use of laboratory-generated samples as sub-
stitutes for clinical samples.
Non-invasive prenatal screening for 22q11.2 deletion
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Subchromosomal abnormalities occur in >1% of pregnancies and are often associated with
severe phenotypes [23]. NIPT has recently expanded its coverage of testing to include a subset
of clinically significant microdeletions. The 22q11.2 DS is a well-defined, severe condition, and
improved clinical outcomes have been demonstrated with prenatal diagnosis [10]. The data
presented in this study add to the growing body of evidence demonstrating the ability of the
SNP-based NIPT to detect 22q11.2 deletions with high sensitivity and specificity [4, 8].
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